Mylan Inc. on Monday said it has agreed to buy Abbott Laboratories’ specialty generic drug business in developed markets outside the U.S. in a $5.3 billion all-stock deal that would allow Mylan to relocate some of its operations to the Netherlands.
The deal calls for Abbott to carve out the assets of its specialty and generic drug business in Europe, Japan, Canada, Australia and New Zealand and transfer them to a new Netherlands-based public company, which will merge with Mylan to create Mylan N.V. In exchange, Abbott will take a 21 percent stake in the combined company, which will be headed by Mylan’s current leadership. Mylan plans to keep its headquarters in Pittsburgh.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
